Wall Street Zen Downgrades iBio (NASDAQ:IBIO) to Sell

iBio (NASDAQ:IBIO) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other brokerages also recently issued reports on IBIO. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a report on Monday, December 29th. Lifesci Capital upgraded shares of iBio to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Leerink Partners raised iBio to a “strong-buy” rating in a report on Friday, October 17th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, iBio has an average rating of “Buy”.

iBio Stock Up 5.2%

Shares of NASDAQ:IBIO opened at $2.22 on Friday. The company has a fifty day moving average of $2.15. iBio has a fifty-two week low of $0.56 and a fifty-two week high of $6.89. The company has a market capitalization of $76.68 million, a PE ratio of -2.22 and a beta of 1.26.

iBio (NASDAQ:IBIO) last issued its quarterly earnings data on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.